NHS England recommends extension of drug to treat non-metastatic prostate cancer

A new NHS clinical commissioning policy has given permission for abiraterone acetate to be prescribed off-label to men with high-risk, hormone sensitive, non-metastatic cancer.…
Published: 27 January 2026